Comparison of the number (mean (SD) of CIL and fat lesions on baseline MRI and after 52 weeks follow-up on adalimumab therapy of 76 patients with ankylosing spondylitis according to whether patients did or did not develop a new syndesmophyte
| With syndesmophyte (n=28) | Without syndesmophyte (n=48) | p Value | |
|---|---|---|---|
| Baseline CIL | 5.2 (4.3) | 2.7 (2.4) | 0.002 |
| Baseline fat lesion | 6.9 (5.7) | 2.8 (3.5) | 0.0003 |
| Baseline type A CIL | 3.9 (3.9) | 2.07 (2.1) | 0.012 |
| Resolved type A CIL | 2.82 (3.08) | 1.53 (1.83) | 0.030 |
| Persistent type A CIL | 1.15 (1.29) | 0.60 (0.84) | 0.032 |
| Baseline type B CIL | 1.33 (1.73) | 0.62 (1.07) | 0.035 |
| Resolved type B CIL | 0.81 (1.36) | 0.29 (0.66) | 0.031 |
| Persistent type B CIL | 0.52 (1.16) | 0.33 (0.71) | 0.065 |
CIL, corner inflammatory lesion.